Sökning: "L-DOPA induced dyskinesia"
Visar resultat 1 - 5 av 23 avhandlingar innehållade orden L-DOPA induced dyskinesia.
Sammanfattning : Parkinson’s disease is a common neurodegenerative disorder caused by nigrostriatal dopamine loss, with motor deficiencies as the primary outcome. To increase the striatal dopamine content, patients are treated with 3,4-dihydroxyphenyl-l-alanine (l-DOPA). LÄS MER
Sammanfattning : Parkinson’s disease is a disorder mainly characterized by progressive degeneration of dopamine producing neurons in the substantia nigra of the midbrain. The most commonly used treatment strategy is to pharmacologically restore the lost function by the administration of the dopaminergic precursor L-DOPA. LÄS MER
Sammanfattning : Parkinson's disease and L-DOPA-induced dyskinesia (LID) does not merely involve the dopamine (DA) system but also include non-dopaminergic systems such as glutamate and serotonin (5-HT). An aberrant glutamate transmission at the corticostriatal synapse, has been linked to LID. LÄS MER
Sammanfattning : This study explores the role of transcriptional regulation important in the development of L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease. In patients with Parkinson’s disease, dyskinesia is one of the most difficult complications of the DA-replacement therapy by L-DOPA. LÄS MER
Sammanfattning : This study has investigated the impact of presynaptic factors on the development of dyskinesia during chronic L-DOPA treatment in a rat model of Parkinson’s disease (PD). The mechanisms causing dyskinesia are not completely understood but have been proposed to involve changes in gene and protein expression in striatal neurons, which are the main target of dopamine (DA) projections from the substantia nigra pars compacta (SNpc). LÄS MER